Trial · NCT00310401
The Effect of Nebulized Albuterol on Donor Oxygenation
NCT00310401, Phase 2, Completed, Vanderbilt University Medical Center; results first posted 2013-09-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Nebulized Albuterol on Donor Oxygenation. Trials, record NCT00310401. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00310401
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Nebulized Albuterol on Donor Oxygenation
- NCT number
- NCT00310401
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 506 participants, actual
- Lead sponsor
- Vanderbilt University Medical Center
- Conditions
- Brain Death, Organ Donor, Pulmonary Edema
- Interventions
- Albuterol, Saline
- First posted
- 2006-04-03
- Last updated
- 2018-03-16
- Results first posted
- 2013-09-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Donor Oxygenation | Change from enrollment to organ procurement (about ~40h after enrollment) | The primary outcome was the change in oxygenation as measured by change in the PaO2/FiO2 ratio from study enrollment to organ procurement |
| Secondary | Number of Donor Lungs Used for Transplantation | 72 hours | Number of lungs procured and used for transplantation |
| Secondary | Lung Compliance | baseline and at organ procurement (about ~40h after enrollment) | Static compliance of the respiratory system using plateau pressure (Pplat) measured at end-inspiration and calculated using the equation static compliance = tidal volume/(Pplat - PEEP) |
| Secondary | Pulmonary Vascular Resistance | 72 hours | |
| Secondary | Chest X-ray Findings | change from enrollment to organ procurement (about ~40h after enrollment) | Chest radiographs were scored using a radiographic score that scored each quadrant for extent of radiographic infiltrates on a scale of 0 to 4, then summed each quadrant for a total score from 0 (no infiltrates) to 16 (extensive infiltrates in all 4 radiographic quadrants). |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Donor Oxygenation | Change from enrollment to organ procurement (about ~40h after enrollment) | cmH2O | MEDIAN | |
| SECONDARY | Number of Donor Lungs Used for Transplantation | 72 hours | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Lung Compliance | baseline and at organ procurement (about ~40h after enrollment) | ml/cmH2O | MEAN | |
| SECONDARY | Pulmonary Vascular Resistance | 72 hours | Insufficient data available to analyze this outcome | ||
| SECONDARY | Chest X-ray Findings | change from enrollment to organ procurement (about ~40h after enrollment) | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Donor Oxygenation | Albuterol | 49 | Inter-Quartile Range -26 to 149 | cmH2O | |
| Donor Oxygenation | Saline | 40 | Inter-Quartile Range -31 to 124 | cmH2O | |
| Number of Donor Lungs Used for Transplantation | Albuterol | 74 | Participants | ||
| Number of Donor Lungs Used for Transplantation | Saline | 78 | Participants | ||
| Lung Compliance | Albuterol | baseline | 48 | Standard Deviation 14 | ml/cmH2O |
| Lung Compliance | Saline | baseline | 50 | Standard Deviation 15 | ml/cmH2O |
| Lung Compliance | Albuterol | at organ procurement (mean ~40h after enrollment) | 52 | Standard Deviation 14 | ml/cmH2O |
| Lung Compliance | Saline | at organ procurement (mean ~40h after enrollment) | 56 | Standard Deviation 38 | ml/cmH2O |
| Chest X-ray Findings | Albuterol | Enrollment | 4.7 | Standard Deviation 3.3 | units on a scale |
| Chest X-ray Findings | Saline | Enrollment | 4.6 | Standard Deviation 3.2 | units on a scale |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Albuterol | 260 | |
| Overall Study | STARTED | Saline | 246 | |
| Overall Study | COMPLETED | Albuterol | 260 | |
| Overall Study | COMPLETED | Saline | 246 | |
| Overall Study | NOT COMPLETED | Albuterol | 0 | |
| Overall Study | NOT COMPLETED | Saline | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Albuterol | ||
| Total, all-cause mortality | Saline | ||
| Total, other adverse events | Albuterol | 0 | 260 |
| Total, other adverse events | Saline | 0 | 246 |
| Total, serious adverse events | Albuterol | 0 | 260 |
| Total, serious adverse events | Saline | 0 | 246 |
Source ClinicalTrials.gov
Papers24
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01HL081332 | Biomarker Profiles in the Diagnosis/Prognosis of ARDS | WARE, LORRAINE B | VANDERBILT UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2005 to 2008 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Albuterol vs Saline: Number of Donor Lungs Used for Transplantation | Trial comparisons |
| Albuterol vs Saline: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00310401
GET https://conductscience.org/api/trials/v1/NCT00310401/papers?page=2